The Japan Blood Products Organization was established in 2012 with the goal of delivering safe and secure blood products made from voluntary donated blood. The company’s donation in 2022 marks its first collaboration with the WFH Humanitarian Aid Program. The donated factor will be used to support patients around the world.
Alain Baumann, WFH CEO, praised the Japan Blood Products Organization for their commitment. “This donation will help us continue the important work that the Humanitarian Aid Program does,” he explains. “It also shows that the momentum from manufacturers to support the global bleeding disorders communities shows no signs of slowing down.”
The addition of the Japan Blood Products Organization to the WFH Humanitarian Aid Program’s group of sponsors proves that the Program’s accomplishments are resonating with a broadening range of organizations across the world. The WFH looks forward to working with more sponsors in the future to support our vision of Treatment for All.
To find out more about the WFH Humanitarian Aid Program, click here.
About the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi and Sobi, our Founding Visionary Contributors; Bayer, CSL Behring and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and Takeda, our Contributor. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org